whose liver function is abnormal. After puberty, a neurological picture is more common, but the signs are pleomorphic. In adolescents, dystonic and choreic signs predominate, whereas pseudosclerosis (resembling multiple sclerosis) or Parkinsonism is more often seen later. 1 Personality changes are not infrequent, and a failing performance at school together with a deterioration in handwriting can be an early warning sign. Other systems that may be involved are osteoarticular, haematological and renal. A patient occasionally presents with joint pains, most commonly in the knees or lumbar spine. Haemolysis occurs in some 10% of cases; it may be acute and severe and when associated with hepatic failure it is immediately lifethreatening and requires urgent liver transplantation. Renal damage as a ¢rst sign is extremely rare, but has been reported. 2 Copper deposition in the cornea gives the characteristic Kayser-Fleischer ring, 3 which is always present in neurological Wilson's disease but is seen in only half of patients with a hepatic presentation. It is probably true to say that no two patients with Wilson's disease are ever quite the same.
The incidence of Wilson's disease has been estimated at 29 per million of the population, with a gene frequency of 0Í53%, 4 but the prevalence is much higher in a paediatric liver-disease clinic or a neurological clinic for adolescents or young adults. As one of the few fatal diseases of the liver or central nervous system for which there is speci¢c and e¡ective therapy, it is a diagnosis that should never be missed.
Genetics
Wilson's disease is inherited in an autosomal recessive manner. The gene, located on chromosome 13q14.3,
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encodes a copper-transporting P-type ATPase (ATP7B) and has close homology with the Menke's gene ATP7A. 5 The gene has 21 exons and the protein has eight transmembrane motifs. Currently, more than 210 mutations are listed in the Wilson's disease database (www.medgen.med.ualberta.ca/database. html). Mutations include small deletions or insertions, nonsense, splice-site and missense mutations, the last-named being the most common, comprising 60% of all mutations. Each ethnic population has speci¢c common mutations, H1069Q being the one most often found in Northern, and particularly Eastern, Europe. 6 For apparent missense mutations, a distinction must be drawn between disease-causing and normal variants. As most patients are compound heterozygotes, phenotype-genotype correlations are di¤cult, but in a small series of homozygous patients seen in Sweden 7 a correlation has been found between the type of mutation and the age of onset of symptoms. In general, mutations predicted to produce a nonfunctional protein are associated with early onset. 5 Exons 8, 12 and 14 are the most common sites for mutations.
DNA analysis for diagnosis can be achieved by the use of sequencing techniques 7 in specialist laboratories but, in practice, it is more commonly used for the detection of mutations in siblings of an established case.When a speci¢c gene cannot be identi¢ed, closely linked microsatellite and £anking DNA markers can be used. 8 Figure 1 shows the results of such a study. The propositus had two younger siblings, one of whom had a normal caeruloplasmin concentration (340 mg/ L), the other, on di¡erent occasions, concentrations between120 and 220 mg/L, which did not distinguish between the heterozygous and homozygous abnormal states. Pedigree analysis (see Fig. 1 ) con¢rmed that she had pre-symptomatic Wilson's disease, a ¢nding in keeping with her inability to incorporate radiocopper into caeruloplasmin and her raised hepatic copper concentration.
Biochemical investigations
No single laboratory test can be considered to be diagnostic for Wilson's disease.When biochemical ¢ndings are interpreted it must be realized that copper accumulation in the tissues is slowly progressive, so that the ¢ndings will depend on the degree of tissue saturation with the metal ion at the time of analysis. Radiochemical studies in the 1970s 9,10 had already shown that decreasing ability of the liver to sequester the metal was correlated with the development of symptoms, which improved as copper was removed by treatment with a chelating agent. It is therefore not possible to make a categorical statement about the speci¢city of any given estimation: the ¢ndings must The biochemical ndings were inconclusive, suggesting that II,2 had Wilson's disease, whereas II,3 was normal. II,1: serum caeruloplasmin 90 mg/L, serum copper 8 ¢ 4 mmol/L, serum 'free' copper 4 ¢ 1 mmol/L; urine copper excretion 5 ¢ 4 mmol/24 h. II,2: serum caeruloplasmin 120-220 mg/L, serum copper 13 ¢ 74 mmol/L, serum 'free' copper 3 ¢ 2-7 ¢ 8 mmol/L; urine copper 2 ¢ 4 mmol/L; liver copper 5 ¢ 1 mmol/g wet weight. II,3: serum caeruloplasmin 340 mg/L. The satellite markers con rmed that II,2 was homozygous for the Wilson's disease gene, whereas II,3 was normal. (Courtesy of Professor DW Cox, to whom the author is grateful.) be interpreted in the light of the clinical and therapeutic history of the patient.
Determination of serum caeruloplasmin concentration is usually considered the most useful screening test for suspectedWilson's disease. Caeruloplasmin is a blue acute-phase protein of M r =132 000. 11 The six atoms of copper in the molecule are not exchangeable in vivo. The apoprotein, without the copper atoms, can also be present in serum. 12^14 Gibbs and Walshe originally showed 14 that the normal mean (standard deviation) caeruloplasmin concentration for men was 333 (60Í7) mg/L and 366 (92Í8) mg/L for women. In patients with untreated Wilson's disease, however, the concentration was much lower: 63Í3 (87Í6) mg/L. However, there was considerable overlap between the heterozygous Wilson's carriers and those individuals with liver or neurological disease and also normal controls.
A single ¢nding of a low concentration of serum caeruloplasmin alone is not su¤cient to establish a diagnosis, as low caeruloplasmin concentrations can also be found in patients with protein-losing enteropathy, nephrotic syndrome, severe protein calorie malnutrition 2 or severe liver disease, 15 as well as in the rare disorder acaeruloplasminaemia. 16 The serum copper must be determined at the same time. The normal range is 14-24 mmol/L (90-150 mg/100 mL), but the important estimation for diagnostic purposes is the non-caeruloplasmin-bound or`free' copper. As caeruloplasmin contains 0Í3% copper,`free' copper can easily be calculated from the total and bound forms (see Appendix 1) . The normal concentration of free' copper is around 1.6 mmol/L (10 mg/100 mL), but in the symptomatic stage of untreated Wilson's disease it can be much higher. In pre-symptomatic and adequately treated Wilson's disease patients, the`free' copper may not be signi¢cantly elevated.
Urinary copper excretion is invariably elevated in symptomatic Wilson's disease. The normal daily excretion under properly controlled conditions is less than 0Í5 mmol (30 mg) per 24 h. Urine collections for copper determination require the use of a wide-necked £ask with a disposable polythene liner. Bedpans, funnels, measuring cylinders and tap water must be eschewed at all costs. In the purely hepatic phase of the illness the daily copper output is usually higher than in the neurological phase, and may reach 6Í3 mmol (400 mg) per 24 h, 17 probably because of a redistribution of copper within the hepatocytes as the illness progresses. 18 In acute hepatic haemolytic disease, urinary excretion may approach 15Í7 mmol (1mg) per day. After a test dose of penicillamine (500 mg for an adult), a symptomatic patient may excrete as much as 47 mmol (3000 mg) or more per day, compared with 4Í7 mmol (300 mg) per day for a normal individual.
Isotope studies with radioactive copper ( 64 Cu, halflife 12Í8 h, or 67 Cu, half-life 61Í6 h) have been much used in the past; the ratio of incorporation of radioactive copper into caeruloplasmin at 24 h to that at 2 h is the simplest useful measurement. 19 In normal subjects, the ratio is around 2Í0, whereas in Wilson's patients it is 50Í3. However, the isotopes have become very expensive and less readily available, and this test has therefore fallen into disuse. The future use of stable copper isotopes will probably be con¢ned to research studies.
Abnormal liver function test results and abnormalities of clotting factors may provide useful con¢rmatory evidence, but they are not of diagnostic signi¢cance. Normal, or only slightly abnormal, liver function tests are not uncommon in neurological Wilson's disease. Liver biopsy can be of great value in establishing the diagnosis. It is necessary to obtain adequate tissue for both histological and chemical study. Histochemical methods of copper staining alone are not su¤ciently reliable to assess the hepatic copper concentration. The earliest histological changes are fatty droplet in¢ltration and ballooned nuclei containing glycogen. Electron microscopy will show changes in the mitochondrial membranes.
For the chemical determination of copper it is preferable to have 15-20 mg of tissue, although estimates can be made on smaller amounts. In very young children it may be desirable to use an open approach under general anaesthesia. If there are clotting problems, a transjugular approach may be used. Fresh frozen plasma and platelets can also be administered. The liver tissue is wet-ashed in sulphuric and perchloric acids and neutraliz ed with 880 ammonia (in ice) for the ¢nal analysis. The normal liver concentration is less than 0Í14 mmol (9 mg) per g wet weight, or less than 0Í8 mmol (50 mg) per g dry weight. In heterozygotes the respective concentrations per g wet and dry weights are up to 0Í8 mmol (50 mg) or up to 4Í0 mmol (250 mg), respectively. Concentrations above these are necessary for a diagnosis of Wilson's disease. Similar or higher concentrations of copper are found in patients with primary biliary cirrhosis, but the two conditions are so di¡erent as to be diagnostically distinct.
Methods for caeruloplasmin determination
Most routine laboratories now use immunological methods, which unfortunately measure both apocaeruloplasmin and caeruloplasmin. 12^14 The former is not relevant, as it does not contain copper and has no enzymatic activity. This point is illustrated in Fig. 2 , which shows results of a comparison of serum caeruloplasmin measured immunochemically and enzymatically. The values obtained immunochemically are almost invariably higher than those obtained enzymatically. Serum caeruloplasmin in the diagnosis of Wilson's disease should therefore be measured by its oxidase activity 12^i .e. as an Fe(II):oxygen oxidoreductase (EC 1.16.3.1). The immunological method will give a falsely low (or even negative) calculated value for`free' copper. In contrast to the results obtained by the enzymatic method (see Table 1 ), these clearly cannot be correct. Furthermore, out of 106 patients seen by the author at the Wilson's disease clinic at the Middlesex Hospital, no fewer than 13 had negative`free' copper concentrations when calculated using the immunochemically determined caeruloplasmin concentration. In contrast, no negative values were obtained when calculated using the enzymatic method. These ¢ndings support the author's view that the immunochemical method should not be used for the diagnosis and management of Wilson's disease. The oxidase determination has the further advantage of a much lower detection limit than the nephelometric one.
The determination of oxidase activity uses pphenylenediamine 20 or its dimethyl derivative 21 as substrate, the latter having the advantage of being less vulnerable to auto-oxidation and therefore giving lower blanks. In the author's laboratory the caeruloplasmin assay was standardized against recrystallized human caeruloplasmin. A further check can be made that the internal quality control sample has a normal`free'copper concentration, as will be found in samples from normal controls and the majority of non-Wilson's patients. In those that do not, factors in serum either potentiate or inhibit oxidase activity (see Fig. 3 ). An additional check used in the author's laboratory 14 was to combine immunoelectrophoresis and oxidase measurement. 
Treatment and follow-up
Penicillamine is still the most widely used chelating agent for the treatment of Wilson's disease. 22 Although it has a wide range of side-e¡ects, 23^28 all are reversible if the drug is stopped in time. One side-e¡ect is an early increase in symptoms on starting treatment, 1 which may result from the generation of free radicals. It has been suggested that the simultaneous administration of a-tocopherol may reduce the risk, but this theory has not yet been tested. Deterioration is seen in 25% of patients with neurological presentation, but this does not usually a¡ect the eventual outcome. 1 A very small number of patients deteriorate rapidly, and in these the drug should be stopped at once and replaced by dimercaprol (British anti-lewisite), 2 given by deep intramuscular injection, 200 mg/day for 5 days a week for 8 weeks, followed by trientine (triethylene tetramine). 29 As both penicillamine and dimercaprol may a¡ect the blood count, this must be monitored in the early stages. Thrombocytopenia is the most common e¡ect, followed by leucopenia, with red-cell depression a rare occurrence. It must be remembered that many patients with liver damage may have low platelet and leucocyte counts when ¢rst seen, and this must be documented so that therapy is not wrongly blamed and unnecessarily withdrawn. Renal damage, with proteinuria, is most commonly due to an autoimmune reaction, immune complex nephritis or systemic lupus erythematosus. The latter may be drug-induced or drug-precipitated, with the drug-precipitated form being the more serious and requiring a change in therapy. Urinary total protein should be measured on each clinic visit as well as the erythrocyte sedimentation rate, as a rise may be the ¢rst sign of trouble.
The chelating agent trientine 30 has fewer side-e¡ects than penicillamine and is equally e¡ective as a treatment. However, it is more expensive and, because of poor intestinal absorption, must be given in a larger dose. Zinc salts have also been used and act by blocking the intestinal absorption of copper rather than promoting its excretion. These agents are best reserved for the maintenance of patients intolerant of other therapies. Zinc can induce iron de¢ciency and sideroblastic anaemia, and is even more likely to do so in combination with trientine, 29, 31 so the two should never be used together.
Tetrathiomolybdate is yet another anti-copper agent, 32 acting both by blocking absorption of the metal and by forming a tight, metabolically inert bond with copper atoms already present in the tissues. It has been shown 33 to induce a reversible bone-marrow depression and also severe skeletal deformities in Ann Clin Biochem 2003; 40: 115-121 Figure 3 . The serum copper concentration plotted against the corresponding serum caeruloplasmin (enzymatic). 'Free' copper is represented by points above the diagonal line, which represents zero 'free' copper. All 74 patients had been referred as cases of Wilson's disease but were found to have other diagnoses. (Most of the 'free' copper values for the points above the line are actually within the reference interval; the few that are signi cantly above and the three signi cantly below the line proved to be due to analytical error, as was shown by cross-checking against the immunoenzymatic method using the Laurell rocket technique.) The two zero caeruloplasmin values were from patients with acaeruloplasminaemia.
growing rats. 34 It should be given with great caution to young patients in whom the epiphyses have not yet fused, and then only in short courses.
Follow-up studies require estimation of the`free' copper, which should be maintained at or near 1¢6 mmol/L (10 mg/100 mL). If after several years of good control the`free' copper concentration starts to increase, this indicates either deteriorating compliance or that a growth spurt or a change in dietary habits has increased the patient's drug requirements.
Liver function tests should be performed on each clinic visit, for apart from other considerations they can be a useful marker of compliance. Deteriorating values indicate the need for an ultrasound examination and possibly a biopsy of the liver. Hepatoma formation is rare in Wilson's disease patients, but cholangiocarcinoma has been reported, as have other abdominal malignancies of undetermined primary site. 35 A brain scan may be indicated if there is progressive neurological disease.
The most useful test for monitoring compliance or adequacy of therapy is determination of the serum free' copper. In the view of the author, this can be properly achieved only if caeruloplasmin is determined enzymatically through measurement of its oxidase activity. 
Appendix 1 Calculation of 'free' copper concentration

